RxDoctor Payments Data

Kalim Habet, MD

Cardiovascular Disease · Brownsville, TXNPI 1306830096

Payments from drug & device makers

$10,965in general payments, 2019–2025

Across 203 payments — averaging $54.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7K
  • Johnson & Johnson$731
  • Amarin Pharma, Inc.$638
  • AstraZeneca$378
  • Merck$315
  • Medtronic$291
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$6,76362%
  • Food & beverage$4,00337%
  • Education$1992%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,965 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$303,319
Medicare patients
733
Services billed
6,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$193,695
EntrestoSacubitril/Valsartan95$160,307
FarxigaDapagliflozin Propanediol57$68,688
XareltoRivaroxaban59$67,468
VascepaIcosapent Ethyl40$27,497
OzempicSemaglutide19$19,324
JardianceEmpagliflozin18$19,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,928
Clonidine85$11,065
Icosapent Ethyl26$10,045
Rosuvastatin Calcium322$4,818
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid25$4,455
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,049
Losartan Potassium306$3,654
Doxazosin Mesylate153$3,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$196$193,695128 claims
NovartisEntresto$7,105$160,30795 claims
AstraZenecaFarxiga$378$68,68857 claims
Johnson & JohnsonXarelto$731$67,46859 claims
Novo NordiskOzempic$49$19,32419 claims
Boehringer IngelheimJardiance$154$19,11518 claims
GSKTrelegy Ellipta$33$14,92813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →